Figure 2

(a) Network plot of comparisons among different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for overall survival for the high-risk group in the chemotherapy naïve setting. Key for (a): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance). Note for (a): Nodes represent the interventions, lines connecting nodes represent direct comparisons between pairs of interventions, the number stated on the lines represents the number of studies involved in the comparisons. (b) Comparative effectiveness of different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for overall survival for the high-risk group in chemotherapy naïve setting. Key for (b): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance). Note for (b): The upper triangle of the matrix displays only the pooled effect sizes of the direct comparisons available in the network. Fields that remain empty in the upper triangle mean that the direct evidence for the comparison is not available. The lower triangle shows the estimated effect sizes for each comparison even when only indirect evidence is available. In the lower triangle of the matrix, values in each cell represent the hazard ratio (HR and 95% confidence interval) of the intervention at the top, compared to the comparator on the left. When HR < 1, prefers the column intervention, indicating that the column intervention is more effective than the row intervention on reducing overall survival. When HR > 1, prefers the row intervention. Significant results are in bold and underlined for both upper and lower triangles. (c) Network plot of comparisons among different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for progression-free survival for the high-risk group in chemotherapy naïve setting. Key for (c): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance), Tre_CM Trebananib (concurrent + maintenance). Note for (c): Nodes represent the interventions, lines connecting nodes represent direct comparisons between pairs of interventions, the number stated on the lines represents the number of studies involved in the comparisons. (d) Comparative effectiveness of different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for progression-free survival for the high-risk group in chemotherapy naïve setting. Key for (d): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance), Tre_CM Trebananib (concurrent + maintenance). Note for (d): The upper triangle of the matrix displays only the pooled effect sizes of the direct comparisons available in the network. Fields that remain empty in the upper triangle mean that the direct evidence for the comparison is not available. The lower triangle shows the estimated effect sizes for each comparison even when only indirect evidence is available. In the lower triangle of the matrix, values in each cell represent the hazard ratio (HR and 95% confidence interval) of the intervention at the top, compared to the comparator on the left. When HR < 1, prefers the column intervention, indicating that the column intervention is more effective than the row intervention on reducing overall survival. When HR > 1, prefers the row intervention. Significant results are in bold and underlined for both upper and lower triangles. (e) Comparative effectiveness of different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for the high-risk group in chemotherapy naïve setting: P-scores for overall survival. Key for (e): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance). Note for (e): The higher the P-scores, the higher likelihood that an intervention is in the top rank or one of the top ranks. (f) Comparative effectiveness of different anti-angiogenic agents and standard of care chemotherapy (i.e., Carboplatin/Paclitaxel) for the high-risk group in chemotherapy naïve setting: P-scores for progression-free survival. Key for (b): Bev_CM Bevacizumab (concurrent + maintenance), Car/Pac Carboplatin/Paclitaxel, Nin_CM Nintedanib (concurrent + maintenance), Tre_CM Trebananib (concurrent + maintenance). Notes for (f): The higher the P-scores, the higher likelihood that an intervention is in the top rank or one of the top ranks.